retatrutide type 2 diabetes phase 2 trial 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Phase 2: Type 2

Several elements of Kind Patches' marketing the customer survey numbers, the implication of GLP-1-like effects, claims about "supporting GLP-1 production" sit close to or in this territory

DAscanio AM, Mullally JA, Frishman WH

It supports digestion, prevents dehydration from diarrhea episodes, and helps maintain regular bowel movements

Learn about Retatrutide (GGG tri-agonist) medication Retatrutide is an up and coming medication, still in clinical trials and does not yet have a known time when it will be approved for use or available to the general public

There's a time when you can take it differently, but I feel like it's just a part of my story and a part of my health journey," says Williams

Despite the limitations, these data suggest that long term therapy is not associated with durable weight loss with withdrawal of the medication and supports guidelines for extended therapy